“Interestingly, BIRC5 and MCL-1 have both been reported to be over-expressed and strongly correlated with progression and ...
BOSTON--(BUSINESS WIRE)--BAKX Therapeutics today announced it closed $25 million in a Series A fundraising led by AB Magnitude Ventures Group with Ipsen Pharma SA and Sherpa Healthcare Partners. The ...
The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluorouracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal ...
Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results